Insights
Insights on health, access and innovation
Read practical thinking from Newmarket Strategy on the policy, access, reimbursement and health system issues shaping healthcare and life sciences.
Patient and public involvement and engagement needs to happen at all levels of healthcare decision making
Patient and public involvement and engagement means that “activities and research are carried out ‘with’ or ‘by’ members of the public or patients, rather than ‘to’, ‘about’ or ‘for’ them”[1].…
Severity modifier – to discount or not to discount?
One of the wins to come out of the recent NICE methods review, according to Industry and others in the Life Sciences ecosystem, was the introduction of the severity modifier.[i] The…
The Innovative Medicines Fund: Regressive Measures or A Worthy Successor?
A new Innovative Medicines Fund (IMF), the NHS England consultation on which closed last Friday, has the potential to make a meaningful impact on patient access to innovative, new medicines in England for…
NHS System reform; a fundamental shift in power or cyclic change?
Last week saw the first hints of the new Health Secretary’s approach to an NHS increasingly used to setting its own agenda. Like so many other public services, political management of the NHS…
NICE Draft Programme Manual – what’s missing?
NICE’s 187-page draft programme manual, published today for consultation, has more than enough by way of reform to HTA methods and processes for any market access aficionado to get their…
UK government publishes 10-year Life Sciences Vision
“Life Sciences will be one of the great drivers of growth in the twenty first century.” The first sentence of the foreword to the British Government’s new Life Sciences Vision…
Events
